Trial Profile
An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Midazolam; Tolbutamide
- Indications Gastrointestinal stromal tumours; Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Apr 2021 Status changed from active, no longer recruiting to completed.
- 16 Feb 2021 Planned End Date changed from 31 Dec 2020 to 1 Sep 2021.
- 07 Apr 2020 Planned End Date changed from 28 Apr 2020 to 31 Dec 2020.